Glucotrack Stock Buy Hold or Sell Recommendation
GCTK Stock | USD 0.25 0.01 3.85% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding GlucoTrack is 'Strong Sell'. The recommendation algorithm takes into account all of GlucoTrack's available fundamental, technical, and predictive indicators you will find on this site.
Check out GlucoTrack Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide. Note, we conduct extensive research on individual companies such as GlucoTrack and provide practical buy, sell, or hold advice based on investors' constraints. GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
GlucoTrack |
Execute GlucoTrack Buy or Sell Advice
The GlucoTrack recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on GlucoTrack. Macroaxis does not own or have any residual interests in GlucoTrack or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute GlucoTrack's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
GlucoTrack Trading Alerts and Improvement Suggestions
GlucoTrack generated a negative expected return over the last 90 days | |
GlucoTrack has high historical volatility and very poor performance | |
GlucoTrack has some characteristics of a very speculative penny stock | |
GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (7.1 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
GlucoTrack currently holds about 3.85 M in cash with (6.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
GlucoTrack has a frail financial position based on the latest SEC disclosures | |
Roughly 35.0% of the company shares are held by company insiders | |
Latest headline from thelincolnianonline.com: GlucoTrack, Inc. Closes Offering and Private Placement, Holding Special Meeting for Stockholder Approval |
GlucoTrack Returns Distribution Density
The distribution of GlucoTrack's historical returns is an attempt to chart the uncertainty of GlucoTrack's future price movements. The chart of the probability distribution of GlucoTrack daily returns describes the distribution of returns around its average expected value. We use GlucoTrack price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of GlucoTrack returns is essential to provide solid investment advice for GlucoTrack.
Mean Return | -2.26 | Value At Risk | -13.89 | Potential Upside | 10.40 | Standard Deviation | 11.72 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of GlucoTrack historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
GlucoTrack Stock Institutional Investors
Shares | Geode Capital Management, Llc | 2024-09-30 | 27.2 K | Alerus Financial Na | 2024-09-30 | 13.9 K | Cetera Investment Advisers | 2024-06-30 | 10 K | Ubs Group Ag | 2024-06-30 | 6.1 K | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 0.0 | Accurate Wealth Management, Llc | 2024-06-30 | 0.0 | Virtue Capital Management, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
GlucoTrack Cash Flow Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 326.0K | 9.4M | (3.8M) | (3.8M) | 2.2M | 2.3M | |
Free Cash Flow | (3.9M) | (3.6M) | (3.8M) | (3.7M) | (6.6M) | (6.2M) | |
Depreciation | 50.6K | 47K | 42K | 23K | 13K | 12.4K | |
Other Non Cash Items | 7.6K | 160K | 44K | 60K | 55K | 57.8K | |
Capital Expenditures | 5.4K | 23.4K | 53K | 5K | 1K | 0.0 | |
Net Income | (3.5M) | (2.7M) | (4.1M) | (4.4M) | (7.1M) | (7.5M) | |
End Period Cash Flow | 475.7K | 9.9M | 6.1M | 2.3M | 4.5M | 2.9M | |
Change To Inventory | 953.0 | (85K) | 293K | 299K | 343.9K | 361.0K | |
Change To Netincome | 519K | 182K | 309K | 499K | 449.1K | 616.2K | |
Investments | (23.4K) | (53K) | (1K) | 1K | 5K | 5.3K |
GlucoTrack Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to GlucoTrack or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that GlucoTrack's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a GlucoTrack stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -2.59 | |
β | Beta against Dow Jones | 2.71 | |
σ | Overall volatility | 12.00 | |
Ir | Information ratio | -0.2 |
GlucoTrack Volatility Alert
GlucoTrack is displaying above-average volatility over the selected time horizon. GlucoTrack is a potential penny stock. Although GlucoTrack may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in GlucoTrack. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on GlucoTrack instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.GlucoTrack Fundamentals Vs Peers
Comparing GlucoTrack's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GlucoTrack's direct or indirect competition across all of the common fundamentals between GlucoTrack and the related equities. This way, we can detect undervalued stocks with similar characteristics as GlucoTrack or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of GlucoTrack's fundamental indicators could also be used in its relative valuation, which is a method of valuing GlucoTrack by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare GlucoTrack to competition |
Fundamentals | GlucoTrack | Peer Average |
Return On Equity | -5.41 | -0.31 |
Return On Asset | -1.57 | -0.14 |
Current Valuation | 3.95 M | 16.62 B |
Shares Outstanding | 8.21 M | 571.82 M |
Shares Owned By Insiders | 34.97 % | 10.09 % |
Shares Owned By Institutions | 0.95 % | 39.21 % |
Number Of Shares Shorted | 257.74 K | 4.71 M |
Price To Book | 21.40 X | 9.51 X |
Gross Profit | (20 K) | 27.38 B |
EBITDA | (7.09 M) | 3.9 B |
Net Income | (7.1 M) | 570.98 M |
Cash And Equivalents | 3.85 M | 2.7 B |
Cash Per Share | 0.25 X | 5.01 X |
Total Debt | 196 K | 5.32 B |
Debt To Equity | 0.06 % | 48.70 % |
Current Ratio | 4.52 X | 2.16 X |
Book Value Per Share | 0.77 X | 1.93 K |
Cash Flow From Operations | (6.56 M) | 971.22 M |
Short Ratio | 6.03 X | 4.00 X |
Earnings Per Share | (2.91) X | 3.12 X |
Number Of Employees | 6 | 18.84 K |
Beta | 0.16 | -0.15 |
Market Capitalization | 2.04 M | 19.03 B |
Total Asset | 4.91 M | 29.47 B |
Retained Earnings | (109.85 M) | 9.33 B |
Working Capital | 3.36 M | 1.48 B |
Net Asset | 4.91 M |
Note: Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3 [view details]
GlucoTrack Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as GlucoTrack . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About GlucoTrack Buy or Sell Advice
When is the right time to buy or sell GlucoTrack? Buying financial instruments such as GlucoTrack Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having GlucoTrack in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
View All Next | Launch |
Check out GlucoTrack Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.91) | Return On Assets (1.57) | Return On Equity (5.41) |
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.